The DOI matches its Crossref record; 316 of the 318 references it cites were found in a registry or an index, and 1 are not checked yet.
Combination strategies to maximize the benefits of cancer immunotherapy
Open accessAbstract
Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy (ACT) have revolutionized cancer treatment, especially in patients whose disease was otherwise considered incurable. However, primary and secondary resistance to single agent immunotherapy often results in treatment failure, and only a minority of patients experience long-term benefits. This review article will discuss the relationship between cancer immune response and mechanisms of resistance to immunotherapy. It will also provide a comprehensive review on the latest clinical status of combination therapies (e.g., immunotherapy with chemotherapy, radiation therapy and targeted therapy), and discuss combination therapies approved by the US Food and Drug Administration. It will provide an overview of therapies targeting cytokines and other soluble immunoregulatory factors, ACT, virotherapy, innate immune modifiers and cancer vaccines, as well as combination therapies that exploit alternative immune targets and other therapeutic modalities. Finally, this review will include the stimulating insights from the 2020 China Immuno-Oncology Workshop co-organized by the Chinese American Hematologist and Oncologist Network (CAHON), the China National Medical Product Administration (NMPA) and Tsinghua University School of Medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accumulating evidence indicates that chemotherapy, radiotherapy, angiogenesis inhibitor, stimulator of interferon genes (STING) agonist, fecal microbiota transplantation (FMT), epigenetic modulators, or other immunomodulators could synergize α-PD-1/PD-L1, by enhancing cancer antigen release, APC function, or effector activity [22–31].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×
“Two coronavirus (COVID-19) mRNA vaccines approved in the US are both RNA vaccines formulated in lipid nanoparticles [285, 286].”
BackgroundCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“Pembrolizumab + pemetrexed /platinum First‐line non‐squamous NSCLC May 10, 2017 [50, 296]”
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Research works printed but not linked: 1
- Shalabi H, Shah NN, Fry TJ, Yates B, Delbrook C, Yuan C, Stetler-Stevenson M, Ramakrishna S. Intensification of lymphodepletion optimizes CAR re-treatment efficacy. Blood. 2017;130(Supplement 1):3889–3889.
Cited by
Sorted by citations
Items 401–500 of 663
Kebo, E., Luo, Y., Wang, X., Liu, R., Tao, H., Zhang, J., Han, Q., Song, Y., & Wang, G. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s584122 · Cited by 4
Jafari, A., Fathi, S., Moosavi, F., & Firuzi, O. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189552 · Cited by 4
Oncolytic Therapy: Delivery System and New Therapeutic Strategies for Cancer
Jin, S., Zhang, Y., Zhou, Z., Zhang, Y., Yu, T., Xu, R., Xu, L., Zhang, J., Zhang, L., Yang, S., et al. (2026) · MedComm · doi:10.1002/mco2.70725 · Cited by 4
Feng, L., Huang, G., Lei, Q., Liang, M., Deng, D., Liu, X., Kong, C., Li, C., Tan, X., Li, G., et al. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400084 · Cited by 4
Xu, D.-M., Chen, L.-X., Zhuang, X., Han, H., & Mo, M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394260 · Cited by 4
Xiang, G., Wang, M., Wang, P., Li, R., Gao, C., Li, Y., Liang, X., Liu, Y., Xu, A., & Tang, J. (2024) · Viruses · doi:10.3390/v16081228 · Cited by 4
Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections
Singh, S. K., & Pancholi, S. S. (2024) · Current Drug Targets · doi:10.2174/0113894501337502241015121015 · Cited by 4
Liu, Y., Yang, L., Duan, Z., Cheng, Q., Liu, M., Zhang, H., & Zhao, H. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1444312 · Cited by 4
Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities
Ruddle, N. H. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-4184-2_16 · Cited by 4
Mao, Z.-C., Chen, L., Chen, X.-M., Lu, X., Mo, Z., Gou, Y., Wei, J.-H., Huang, R.-Z., & Zhang, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117338 · Cited by 4
Meyers, M., Awada, A. H., Najmaoui, M., Ilzkovitz, M., Pezzullo, M., Chaves, J., Deviere, J. M., Halenarova, K. W., Georgala, A., Fastrez, M., et al. (2025) · Case Reports in Oncology · doi:10.1159/000543518 · Cited by 4
Wang, L., Li, Q., Sun, Y., Wang, S., Fu, X., 王秀芬, Zheng, Y., Gao, A., Sun, Y., & Li, J. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102381 · Cited by 4
Yang, Z., Wang, L., & Kang, F. (2025) · International Journal of Cancer · doi:10.1002/ijc.35496 · Cited by 4
Liu, Y., Wang, L., Kong, F., Liu, T., & Liu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1651165 · Cited by 4
Self-citationRole of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives
Garg, P., Singhal, G., Pareek, S., Khan, A., Tan, T., Wheeler, D. L., & Singhal, S. S. (2025) · Cancer treatment and research · doi:10.1007/978-3-031-97242-3_10 · Cited by 4
Novel PD-L1 Small-Molecule Inhibitors Advancing Cancer Immunotherapy
Awadasseid, A., Wu, M., Zhang, F., Song, Y., Wu, Y., & Zhang, W. (2025) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206393267250912114756 · Cited by 4
Li, J., Zhang, H., Zhu, H., & Li, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111176 · Cited by 4
Kumar, P., Yadav, U. P., Joshi, G., Arora, S., Kumar, M., Chatterjee, J., Chandra, V., Singh, S., Kumar, R., & Kumar, S. (2024) · ChemistrySelect · doi:10.1002/slct.202400223 · Cited by 4
Transcriptional dysregulation and insights into clinical implications in melanoma
Shen, C., Chen, M., Nian, X., Li, J., & Tao, J. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00091-y · Cited by 4
Jin, I., Lee, S., Schmuhalek, M., & Nam, H. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae717 · Cited by 5
Regulatory Aspects of Cancer Immunotherapy
Ganeshpurkar, A., Ganeshpurkar, A., Prajapati, H., Saxena, N., Jain, S., & Dubey, N. (2024) · Springer eBooks · doi:10.1007/978-981-97-7022-9_17 · Cited by 4
Chou, M.-Y., & Yang, M. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102353 · Cited by 4
Tanaka, M., & Abe, S. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175206 · Cited by 4
Ma, S., Zhu, J. W., Wang, M., Zhu, J., Wang, W., Xiong, Y., Jiang, R., Liu, L., & Jiang, T. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.996950 · Cited by 4
Immunotherapy approaches for rare pediatric solid tumors: advances and future directions
Pineda, J. C. F., Wedekind, M. F., & Glod, J. W. (2022) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001206 · Cited by 5
Exploring TLR signaling pathways as promising targets in cervical cancer: The road less traveled
Agarwal, M., Kumar, M., Pathak, R., Bala, K., & Kumar, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2023.11.005 · Cited by 4
Xu, J., Song, M., Zhou, F., Zheng, L., Wang, J., & Liu, K. (2023) · Materials & Design · doi:10.1016/j.matdes.2023.112232 · Cited by 3
Self-citationWojciechowicz, K., Kuncewicz, K., Rutkowski, J., Jassem, J., Wardowska, A., & Spodzieja, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362152 · Cited by 3
Enhancing cancer care with improved checkpoint inhibitors: a focus on PD-1/PD-L1
A S, V., Infant, S. S., Saravanan, A., Sivakumar, V. L., Thamarai, P., Manikandan, S., Chopra, S., & Chopra, H. (2024) · EXCLI journal · doi:10.17179/excli2024-7783 · Cited by 3
Li, J., Wu, Y., Ye, P., Zuo, D., Deng, S., Pang, R., & Li, H. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.117925 · Cited by 3
Jiang, P., Li, F., Jiang, Z., Sun, Y., Yang, F., Chu, L.-S., Gai, Y., & Wang, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.15183 · Cited by 3
Approaches to modeling cancer metastasis: from bench to bedside
Sun, L., Zhou, Y., Yin, M., Wang, F., & Yang, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1602489 · Cited by 3
Fan, X., Li, Z., & Liu, D. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1652917 · Cited by 3
Self-citationLi, Y., Zheng, R., Pan, B., Wang, X., Zhang, L., Gao, H., & Li, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1713199 · Cited by 3
Enneiymy, M., Rahhou, A. E., Elmachkouri, Y. A., Hasnaoui, A., Taha, M. L., Itto, M. Y. A., Alotaibi, S. H., Oubella, A., & Haggam, R. A. (2025) · Journal of Fluorescence · doi:10.1007/s10895-025-04622-2 · Cited by 3
Chen, Y. C., Du, Y., Ni, J., Wang, D., Zhan, P., Song, Y., Han, H., & Lv, T. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251405044 · Cited by 3
Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review
Hu, G., Li, Z., Chen, Y., Liao, H., & Zhou, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664587 · Cited by 3
Self-citationBoos, M. A., Seifert, O., Sawall, S., Genz, J., Huber, A., Hofmann, I., Kontermann, R. E., Ungerechts, G., & Nettelbeck, D. M. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201106 · Cited by 3
Advances in targeted protein degradation for cancer immunotherapy
Sun, Y., Li, M., Zou, Y., & Shi, B. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100403 · Cited by 3
Kumar, S., Jindal, A., Mainuddin, Rastogi, H., & Kumar, A. (2026) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c02297 · Cited by 3
Wu, R.-T., Zhang, J., Fang, C.-N., Qi, X.-Y., Qiao, J.-F., Li, P., & Su, L. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i35.8385 · Cited by 3
Kadian, P., Kesari, A., Singh, I. R., Choudhury, S., Singh, A. K., Panda, J. J., & Randhawa, J. K. (2024) · Langmuir · doi:10.1021/acs.langmuir.4c01466 · Cited by 3
Zheng, L., Hu, F., Nie, W., Lu, J., Zhang, B., Xu, J., Wang, S., Li, Y., Zheng, X., Zhang, W., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70223 · Cited by 3
Self-citationGaloian, K. A., Bilbao, D., Denny, C., Gallego, N. C., Roberts, E. R., Martinez, D., & Temple, H. T. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200905 · Cited by 3
An, Q., Ping, Z., Wang, H., Zhang, Z., Liu, S., Bai, W., Zhu, H., Zhen, C., Qiao, X., Yang, L., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.109546 · Cited by 3
Hou, Y., Yang, X., & Meng, H. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00140-6 · Cited by 3
Ovechkina, V. S., Andrianova, S. K., Shimanskaia, I. O., Suvorova, P. S., Ryabinina, A. Y., Blagonravov, M. L., Belousov, V. V., & Mozhaev, A. A. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00842 · Cited by 3
Shukla, S., Khairnar, P., Hedaoo, A., Phatale, V., Vambhurkar, G. B., Wagh, S. S., Sharma, A., & Srivastava, S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106811 · Cited by 3
Zhao, L., Zhang, Z., Wang, D., Liu, Y., Liu, Z., & Lou, C. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01623-0 · Cited by 3
Forster, J., Fish, A., Malhotra, M., Pinjari, A., Debnath, M., & Kulkarni, A. A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503771 · Cited by 3
Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells
Ko, Y., Jeong, Y. H., & Lee, J. A. (2022) · Cells · doi:10.3390/cells11142164 · Cited by 3
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David, É., Perez, C., & Rodallec, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112326 · Cited by 3
Immunological Assessment of Recent Immunotherapy for Colorectal Cancer
Das, S., & Acharya, D. (2023) · Immunological Investigations · doi:10.1080/08820139.2023.2264906 · Cited by 3
Oncology Combination Dose‐Finding Study Design for Targeted and Immuno‐Oncology Therapies
Zhou, L., Reddy, M. B., Mittapalli, R. K., Yang, J., & Yin, D. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3085 · Cited by 3
Li, H., Ruan, Z., Jia, Y., Zhang, Y., Wang, L., Yang, Y., Wang, R., & Fang, J. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16242 · Cited by 3
Mao, Y., Wang, A., Ge, X., Zhai, J., Hu, Y., & Wang, J. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03791-x · Cited by 3
Matsuda, K., Ota, Y., Uemachi, H., Taoda, R., Tsunashima, Y., Ban, H., & Nagai, Y. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156842 · Cited by 2
Yang, C., Du, J., Qiu, X., Jia, C., Ding, C., Wu, Y., Gao, C., Wang, W., Wang, X., & Liu, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02194-y · Cited by 2
Yang, X., & Lin, X. (2025) · Medicine · doi:10.1097/md.0000000000043636 · Cited by 2
Liu, Y., You, Y., Chen, L., Li, J., Yuan, M., Duan, B., Ge, H., Chen, X., Yang, L., Chen, X., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11904-7 · Cited by 2
Comprehensive analysis of MAGE-A10 in pan-cancer and its validation in gastric cancer
Yin, Y., Wang, B., Yang, M., Liu, W., Wang, A., Lu, Z., Chen, J., & Li, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-17987-y · Cited by 2
Targeting ILT4 to Improve Immunotherapy Efficacy in Solid Tumour: From Bench to Bedside
Gao, A., Wang, S., & Sun, Y. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s548082 · Cited by 2
Huang, L., Wu, J., Sun, Y., Yang, Y., & Liu, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-03295-4 · Cited by 2
Tu, H., Lin, D., & Chen, C. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s544565 · Cited by 2
Rongrong, C. (2025) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2025.102602 · Cited by 2
Shan, X., Bai, H., Ning, H., Xie, C., Chen, Y., Xing, S., Ni, D., Guo, X., Zeng, J., & Hu, L. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03321-w · Cited by 2
Yu, Z., Li, F., Quan, Y., Hu, W., Zhang, P., & Xie, X. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48010079 · Cited by 2
Zhou, J., Ye, W., Ranarisoa, S. N., & Tian, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1775409 · Cited by 2
Miao, F., Lu, J., Zhao, Y., Wang, W., Zhang, T., Liu, J., Zhang, X., Wu, L., Yan, H., Wang, R., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.202522249 · Cited by 2
Self-citationJiang, Y., Zheng, L.-L., Fu, M., & Zheng, B.-J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1820652 · Cited by 2
Self-citationBonet, C., Rizzolo-Brime, L., Montañés, S., Hajji-Louati, M., Marques, C., Severi, G., Schulze, M. B., Dahm, C. C., Tjønneland, A. M., Olsen, A. B., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70486 · Cited by 2
Zhu, Y., Tang, Y., Chen, Y., Zhang, Z., Lu, Y., Wang, X., Shi, Q., Zhao, W., & Pang, H. (2026) · Advanced Science · doi:10.1002/advs.75818 · Cited by 2
Chen, Q., & Du, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.948102 · Cited by 2
[Advances of Immunotherapy Resistance and Coping Strategies in Non-small Cell Lung Cancer].
Jing, Y., Zeng, H., Cheng, R., Tian, P., & Li, Y. (2023) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.102.03 · Cited by 2
Hao, Y., Li, R., & Min, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00946 · Cited by 2
Zhu, Y., & Lu, Y. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1756 · Cited by 2
Li, W., Chen, Z., Lu, M., Lu, Z., Fu, S., Wu, Y., Tao, H., Shi, L., Ma, T., & Wang, J. (2024) · Malignancy Spectrum · doi:10.1002/msp2.41 · Cited by 2
Jin, X., Hu, Z., Yin, J., Shan, G., Zhao, M., Liao, Z., Liang, J., Bi, G., Cheng, Y., Xi, J., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36599 · Cited by 2
Delivery of imiquimod to intestinal lymph nodes following oral administration
Chen, H., Ji, L., Wong, A., Chu, Y., Feng, W., Zhu, Y., Wang, J., Comeo, E., Kim, D., Stocks, M. J., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124895 · Cited by 2
Deng, F., Ye, H., Zhang, P., Xu, J., Li, Y., Sun, M., & Yang, Z. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15492 · Cited by 2
Abushanab, A. K., Mustafa, M. T., Mousa, M. T., Albanawi, R. F., Alkhalaileh, R. M., Al-Qudah, G., Zaina, R. F. A., Sitta, Z. A. A., Almasri, I. M., & Abuquteish, D. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2460537 · Cited by 2
Mo, J., Cai, Q., Chen, S., Luo, J., Hu, Z., Su, L., Cheng, L. L., Huang, L., Liu, S., Wang, X., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112801 · Cited by 2
Kong, F., Jiang, J., Chernova, E. A., Wuttke, S., Zhu, W., & Lei, Q. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502358 · Cited by 2
Cui, S., Zhao, K., Wang, N., Meng, Y. G., Zhao, C., Liu, H., Wen, X., & Kong, F. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01353-1 · Cited by 2
Self-citationLuo, T., Geng, H., Wang, G., Zhao, Y. R., Han, N., Ouyang, T., Chen, A., Liu, X., Chen, C., & Yang, M. Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643591 · Cited by 2
Chen, P.-C., Su, B., Ma, T.-L., Hong, Y. C., Chen, Y., Vo, T. T. T., Wu, L.-Y., Peng, T., Wang, C., & Lee, I. (2023) · Applied Sciences · doi:10.3390/app13074340 · Cited by 2
Closing Editorial: Colorectal Cancer—A Molecular Genetics Perspective
Gharib, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312604 · Cited by 2
Zhang, S., Yang, L., Yang, Y., Xin, Y., & Wang, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14696 · Cited by 1
Trends in Immunotherapy Clinical Trials to Treat Glioblastoma: A Look at Progress and Challenges
Price, G. A., Rossitto, C. P., Price, H., Hadjipanayis, C. G., & Martini, M. L. (2023) · World Neurosurgery · doi:10.1016/j.wneu.2023.08.020 · Cited by 1
The Role of Newcastle Disease Virus in Cancer Therapy: A Systematic Review
Rajaei, N., Faraji, N., Borhani-khabaz, P., Yousefi, M., Khavidaki, N. L., & Omranzadeh, A. (2023) · Journal of World s Poultry Research · doi:10.36380/jwpr.2023.40 · Cited by 1
Ying, L., Kong, L., Qiu, X., Cheng, A., Wang, Q., Xiu, L., Shi, J., Tao, Y., & Chai, Z. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18265 · Cited by 1
Meng, Y., Han, H., Zhu, S., Li, C., Li, H., Wang, Z., Wu, R., Wang, Y., Zhang, Q., Gong, Y., et al. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03712-0 · Cited by 1
Self-citationExploring the potential of bi-specific antibodies in cancer immunotherapy
Eskandar, K. (2025) · Surgery and Oncology · doi:10.17650/2949-5857-2025-15-1-11-17 · Cited by 1
Cancer Immunology and Immunotherapy
Wang, G.-R., Cao, L., Xu, Z., Liu, B., Wu, Q., & Bu, L. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_1 · Cited by 1
Wang, W., Li, Y., Li, S., Lin, F., Guo, J., Liu, F., Abudusaimaiti, G., Liu, J., & Sun, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-99909-6 · Cited by 1
IFNα2b in combination with oncolytic adenovirus enhances antitumor activity against melanoma
He, Q., hao, T., She, D., & Lv, P. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115435 · Cited by 1
Comparative Analysis of Chemotherapy and Immunotherapy in Treating Advanced Cancer
Manoli, P. A., Gudur, R. A., Khurana, J., Sharma, A., & Reddy, P. (2025) · Health Leadership and Quality of Life · doi:10.56294/hl2025855 · Cited by 1
Zhang, L., Liu, S., Wang, D., Zhang, X., Hu, Z., Zou, X., Li, X., Wang, X. J., Xu, D., Liu, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-18290-6 · Cited by 1
Khan, A. A., Aptekmann, A. A., Min, D., Povelaitis, M., Lee, S., & Ryu, B. (2025) · Cells · doi:10.3390/cells14211699 · Cited by 1
Chen, Y., Chen, Z., Guo, H., Zhou, H., Deng, Y., Wang, R., Han, F., Mao, H., Zhang, Z., Wu, Y., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71329 · Cited by 1
Metadata
- Authors
- Zhu, S., Zhang, T., Zheng, L., Liu, H., Song, W., Liu, D., Li, Z., & Pan, C.-X.
- Affiliations
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Duke University (US)
- Johns Hopkins University (US)
- University of Chicago (US)
- New York Medical College (US)
- The Ohio State University (US)
- Harvard University (US)
- Corresponding author
- Li, Zihai
- Pan, Chong-xian
- Venue
- Journal of Hematology & Oncology
- Published
- 2021-09-27
- Volume
- 14
- Issue
- 1
- Pages
- 156-156
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC8475356
- OpenAlex
- W3202901824
- Cited by
- 654
- References
- 318
- Citations by year
- 2026: 78 · 2025: 163 · 2024: 206 · 2023: 127 · 2022: 77 · 2021: 2
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Touro Scholar (Touro College) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Tsinghua University
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, combination therapy, immune checkpoint blockade, adoptive immunotherapy, immunotherapy resistance, cancer vaccines, virotherapy, cytokine-targeted therapy, combination chemotherapy, radiation therapy combination, combination targeted therapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Combined Modality Therapy, Humans, Immunotherapy, Neoplasms, Cancer Vaccines, Oncolytic Virotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
